The administration’s plan to nominate Scott Gottlieb as FDA commissioner drew generally positive reactions on Capitol Hill and from device makers — but also some concerns from other stakeholders over his strong industry ties.

The Advanced Medical Technology Association (AdvaMed) said Gottlieb’s background and commitment to technological innovation make him a strong choice to lead the FDA. Gottlieb previously served as an FDA deputy commissioner. AdvaMed President and CEO Scott Whitaker said his group looks forward to working with Gottlieb on the medical device user fee reauthorization.

The Association of Clinical Research Organizations said it “applauds the thoughtful nomination,” and said it believes Gottlieb will strike the appropriate balance of encouraging innovation while ensuring the safety and efficacy of new drugs.